Sign Out
Carboplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.
Bone marrow suppression is dose-related and may be severe, resulting in infection and/or bleeding.
Anemia may be cumulative and may require transfusion support.
Carboplatin can induce emesis. The incidence and intensity of emesis can be reduced by using premeditation with antiemetics.
Anaphylactic-like reactions to Carboplatin have been reported and may occur within minutes of carboplatin administration. Epinephrine, corticosteroids and antihistamines have been employed to alleviate symptoms.
Carboplatin has limited nephrotoxic potential but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity and caution must be exercised when a patient receives both drugs.
Peripheral neurotoxicity is infrequent, its incidence increases in patients older than 65 years and in patients previously treated with cisplatin.
Loss of vision, which can be complete for light colors, may occur after the use of carboplatin with doses higher than those recommended. Vision appears to recover totally or to a significant extent within weeks of stopping these high doses.
Needles or intravenous administration sets containing aluminum part that may come in contact with Carboplatin should not be used for the preparation or the administration of the drug. Aluminum can react with carboplatin causing precipitate formation and loss of potency.
Carboplatin is mutagenic both in-vitro and in-vivo.
Use in Pregnancy: Carboplatin may cause foetal harm when administered to a pregnant woman and is embryotoxic and teratogenic in rats. If this drug is used during pregnancy, the patient should be apprised of the potential hazard to the foetus. Woman of child bearing potential should be advised to avoid becoming pregnant.
